Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

This study has been completed.
Information provided by (Responsible Party):
Imperial College London Identifier:
First received: March 25, 2011
Last updated: May 20, 2014
Last verified: December 2011

This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects currently attending for HIV care at St. Mary's Hospital, London will be eligible.

The study will describe the steady state pharmacokinetic parameters and short term safety of maraviroc/darunavir/ritonavir dosed at 150/800/100 mg once daily with and without tenofovir/emtricitabine 245/200 mg once daily in HIV-1 infected subjects.

Fifteen HIV-1 infected subjects will be recruited. Eligible subjects will currently be receiving antiretroviral therapy comprising:

  • tenofovir/emtricitabine 245/200 mg daily plus
  • darunavir/ritonavir 800/100 mg daily

On day 1, subjects will modify their current antiretroviral therapy to the following:

  • tenofovir/emtricitabine 245/200 mg daily plus
  • darunavir/ritonavir 800/100 mg daily plus
  • maraviroc 150 mg daily On day 10 subjects will undergo an intensive pharmacokinetic visit.

On day 11, subjects will modify their current antiretroviral therapy to the following:

  • darunavir/ritonavir 800/100 mg daily plus
  • maraviroc 150 mg daily (i.e. tenofovir/emtricitabine will be discontinued) On day 20 subjects will undergo an intensive pharmacokinetic visit. Following completion of this study phase, subjects will recommence their usual antiretroviral treatment regimen and attend for a study follow up visit.

Condition Intervention Phase
Drug: Maraviroc
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • maximum plasma concentration [ Time Frame: 20 days ]
    On day 10 of the study the maximum and minimum plasma concentractions of darunavir, ritonavir maraviroc tenofovir and emtricitibine will be measured and the time to reach these levels. On day 20 of the study the maximum and minimum plasma concentractions of darunavir, ritonavir and maraviroc will be measured and the time to reach these levels.

Secondary Outcome Measures:
  • Changes in haematology and biochemistry laboratory tests [ Time Frame: 35 days ]
    full blood count, elelectrolytes and lipids will be measured to assess for changes

Enrollment: 12
Study Start Date: October 2011
Study Completion Date: May 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Truvada, Darunavir/r and Maraviroc
Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Drug: Maraviroc
Maraviroc 150 mg daily


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infected males or females
  • signed informed consent
  • plasma HIV RNA < 50 copies/mL at screening and on at least one other occasion over the last 3 months
  • currently receiving an antiretroviral regimen comprising of: tenofovir 245 mg daily,emtricitabine 200 mg daily, darunavir 800 mg daily and ritonavir 100 mg daily
  • no previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing if an HIV resistance test available
  • Between 18 to 65 years of age, inclusive
  • subjects in good health upon medical history, physical exam, and laboratory testing
  • BMI above or equal to 18 and below 32
  • Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening until 8 weeks after completion of the study:
  • barrier contraceptives (condom OR diaphragm PLUS spermicide) or oral, implant or injectable hormonal contraceptive PLUS a barrier contraceptive or
  • IUD /IUS PLUS a barrier contraceptive
  • Female subjects of childbearing potential must have a negative urine pregnancy test.
  • Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study.
  • Have no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen and no serologic evidence of hepatitis C virus infection evidenced by a negative HCV antibody at screening.
  • Have screening laboratory results (haematology and chemistry that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical significance
  • CCR5 tropic HIV virus based on a genotypic tropism assay from either a stored plasma sample where available or fresh plasma

Exclusion Criteria:

  • current alcohol abuse or drug dependence
  • positive urine drug of abuse screening
  • pregnancy
  • active opportunistic infection or significant co-morbidities
  • current disallowed concomitant medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01348763

United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom, W2 1NY
Sponsors and Collaborators
Imperial College London
Principal Investigator: Alan Winston, MB BH Imperial College London
  More Information

Responsible Party: Imperial College London Identifier: NCT01348763     History of Changes
Other Study ID Numbers: MRV_DRV_PK
2009-014924-42 ( EudraCT Number )
Study First Received: March 25, 2011
Last Updated: May 20, 2014

Additional relevant MeSH terms:
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
CCR5 Receptor Antagonists processed this record on May 25, 2017